KDNY · Chinook Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.01M | $1.83M | - | $2.50M | $418.0K | $2.70M | - | $4.0K | $34.0K | $351.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $57.90M | $50.88M | - | $41.98M | $30.02M | $26.25M | - | $23.57M | $22.79M | $25.70M |
| SG&A | $13.06M | $11.40M | - | $10.02M | $8.63M | $7.87M | - | $6.85M | $7.77M | $9.54M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | $37.50M |
| D&A | $1.50M | $900.0K | - | $800.0K | $800.0K | $700.0K | - | - | - | - |
| Operating Income | ($72.63M) | ($61.42M) | - | ($57.68M) | ($36.69M) | ($30.81M) | - | ($31.01M) | ($43.27M) | ($37.15M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | - | $0 | $0 | $0 | - | ($463.0K) | ($741.0K) | $0 |
| Net Income | ($66.94M) | ($60.18M) | - | ($55.98M) | ($37.65M) | ($31.68M) | - | ($30.70M) | ($42.57M) | ($37.22M) |
| EPS - Basic | ($0.94) | ($0.54) | - | ($0.69) | ($0.61) | - | - | - | - | - |
| EPS - Diluted | ($0.94) | ($0.85) | - | ($0.83) | ($0.97) | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $127.15M | $118.50M | $115.44M | $126.07M | $145.93M | $103.50M | $181.72M | $108.52M | $135.47M | $168.09M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $16.36M | $9.77M | $9.75M | $11.84M | $4.91M | $9.04M | $8.58M | $5.51M | $9.22M | $7.36M |
| Current Assets | $305.42M | $358.64M | $385.59M | $381.67M | $371.40M | $285.77M | $300.64M | $186.54M | $203.33M | $226.00M |
| Total Assets | $488.81M | $543.88M | $574.08M | $590.34M | $601.24M | $531.27M | $563.80M | $383.28M | $407.87M | $398.77M |
| Current Liabilities | $52.47M | $50.96M | $50.84M | $44.74M | $29.48M | $36.57M | $40.09M | $23.57M | $23.77M | $24.98M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $131.77M | $131.48M | $132.14M | $115.70M | $94.11M | $104.47M | $110.16M | $113.50M | $111.14M | $98.25M |
| Stockholders' Equity | $357.04M | $412.39M | $441.94M | $474.64M | $507.13M | $426.80M | $453.64M | $269.78M | $296.73M | $300.52M |
| Retained Earnings | ($546.75M) | ($479.81M) | ($419.63M) | ($357.08M) | ($301.10M) | ($263.45M) | ($231.77M) | ($239.31M) | ($208.62M) | ($166.04M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($50.67M) | - | - | - | ($24.72M) | - | - | - | ($28.08M) |
| Investing Cash Flow | - | $32.43M | - | - | - | ($55.57M) | - | - | - | $7.83M |
| Financing Cash Flow | - | $21.27M | - | - | - | $1.76M | - | - | - | $580.0K |
| CapEx | - | $927.0K | - | - | - | $374.0K | - | - | - | $594.0K |
| Free Cash Flow | - | ($51.59M) | - | - | - | ($25.10M) | - | - | - | ($28.68M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -7205.0% | -3359.8% | - | -2306.2% | -8776.3% | -1142.5% | - | -775150.0% | -127273.5% | -10583.5% |
| EBITDA margin | -7056.2% | -3310.6% | - | -2274.2% | -8584.9% | -1116.6% | - | - | - | - |
| Net margin | -6641.3% | -3292.0% | - | -2238.3% | -9006.7% | -1174.8% | - | -767400.0% | -125208.8% | -10602.6% |
| Free cash flow margin | - | -2822.5% | - | - | - | -930.5% | - | - | - | -8169.5% |
| FCF / Net income | - | 0.86 | - | - | - | 0.79 | - | - | - | 0.77 |
| R&D / Revenue | 5743.8% | 2783.5% | - | 1678.7% | 7182.5% | 973.4% | - | 589325.0% | 67020.6% | 7321.1% |
| SG&A / Revenue | 1295.7% | 623.9% | - | 400.8% | 2065.8% | 291.7% | - | 171175.0% | 22847.1% | 2718.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.7% | -11.1% | - | -9.5% | -6.3% | -6.0% | - | -8.0% | -10.4% | -9.3% |
| Return on equity | -18.7% | -14.6% | - | -11.8% | -7.4% | -7.4% | - | -11.4% | -14.3% | -12.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.82 | 7.04 | 7.59 | 8.53 | 12.60 | 7.82 | 7.50 | 7.91 | 8.55 | 9.05 |
| Quick ratio | 5.82 | 7.04 | 7.59 | 8.53 | 12.60 | 7.82 | 7.50 | 7.91 | 8.55 | 9.05 |
| Cash ratio | 2.42 | 2.33 | 2.27 | 2.82 | 4.95 | 2.83 | 4.53 | 4.60 | 5.70 | 6.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.37 | 1.32 | 1.30 | 1.24 | 1.19 | 1.24 | 1.24 | 1.42 | 1.37 | 1.33 |
| Liabilities / Assets | 0.27 | 0.24 | 0.23 | 0.20 | 0.16 | 0.20 | 0.20 | 0.30 | 0.27 | 0.25 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.01 | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 141.1% | -32.2% | - | 62425.0% | 1129.4% | 668.4% | - | -99.9% | -99.4% | -97.5% |
| Revenue CAGR (3y) | -43.5% | -49.2% | - | -19.5% | -55.9% | -11.9% | - | -89.1% | -82.1% | -62.4% |
| Revenue CAGR (5y) | -29.8% | -22.7% | - | -8.0% | -41.1% | -6.5% | - | -74.6% | -75.6% | -38.6% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -98.0% | -99.3% | - | -86.0% | 15.2% | 17.1% | - | -108.0% | -154.5% | -162.7% |
| Net income growth (YoY) | -77.8% | -89.9% | - | -82.4% | 11.6% | 14.9% | - | -111.1% | -156.2% | -391.3% |
| EPS growth (YoY) | 3.1% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -105.6% | - | - | - | 12.5% | - | - | - | -262.4% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -29.6% | -3.4% | -2.6% | 75.9% | 70.9% | 42.0% | 35.6% | 681.2% | 536.5% | 404.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CHINOOK THERAPEUTICS against the 5 most active filers in the same SIC group.